Openbookopenbook
Equity
SSY Group Limited(LJUIF)
USD --+0.00%
Reward52Moderate
Risk39Moderate
📊75%Data
36.0% dividend yield · Revenue down 36% YoY
LJUIF
+0.0 · +0.00%
USD · PINK
SSY Group Limited | Healthcare
Dividend King
Market Cap:1.17Bn
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
39
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on LJUIF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is SSY Group Limited?

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally.

LJUIF · Verdict

Moderate reward · moderate risk

LJUIF's standout is volatility, while valuation remains the main concern.

Based on 88% data coverage

LJUIF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility80/100

    Top decile vs peers

Watchouts 1

  • Valuation41/100

    Below average

Model-based scoring. For information only — not financial advice.

What is SSY Group Limited?

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.17B, and a P/E ratio of 13.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with profitability and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.17B
P/E Ratio13.4183
Dividend Yield36.02%
52 Week High0.43
52 Week Low0.38
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding3B
No. of Employees5,700
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.535
CurrencyUSD · Reports in HKD
Websitewww.ssygroup.com.hk
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.